Clalit's $50M Pediatric Venture Fund: Who Gains From Donor-Advised Giving
Schneider Children's Medical Center launches Israel's first pediatric healthcare venture fund with $20M raised and targeting $50M total.
The Announcement That Signals a Funding Shift
Schneider Children's Medical Center, part of the Clalit Health Services group, is establishing Schneider Children's VC (SCVC), an investment fund focused on innovation in pediatric healthcare. The fund launched publicly on November 4, 2026, after eight months in "stealth mode," quietly recruiting initial investors.
The fund has raised $20 million in its initial closing and has already invested in three companies. Individual cheques range from $500,000 to $3 million. The larger ambition is significant: SCVC is the first fund in israel dedicated to pediatric healthcare.
This is not a typical charity announcement. SCVC operates as a for-profit fund with a social mission. More importantly, a third of the interest that the fund generates will go back to Clalit and Schneider for research, and the fund is working with donor-advised funds to allow funders to invest — and potentially grow — their charitable donations.
The Pediatric Gap: Why This Fund Exists Now
Despite children representing roughly 30% of israel's population, pediatric health draws only a sliver of venture capital. Although children account for approximately 30% of Israel's population, many of the technologies and medications used in pediatric care were originally developed for adults.
This gap has real consequences. The venture capital ecosystem has historically prioritized adult healthcare, leaving pediatric innovation underfunded despite the potential for prevention and long-term health impact. Operations began in February after an agreement with Clalit, and the fund has since evaluated about 170 companies.
Anchor investors include Schneider, Clalit, the Dor Group, and Ronen Gadot, who serves as managing partner. The institutional backing matters: The fund highlights its unique advantage in utilizing data other health-focused funds do not have access to, paired with AI tools it has been developing.
How Donor-Advised Funds Unlock Capital for Health Innovation
Understanding the mechanism is essential for potential investors. A Donor Advised Fund (DAF) is a philanthropic giving vehicle that allows you to make a charitable contribution, receive an immediate tax benefit, and recommend grants to charities over time. In Israel's context, this vehicle is relatively new but growing rapidly.
Keshet, a public-benefit company established in 2019 to maximize philanthropic resources in Israel, is the largest fund in Israel for managing private philanthropy. Keshet recently released its 2025 year in review report, showing a major expansion, with NIS 420 million ($132.7 million) deposited last year for a total of NIS 1.3 billion ($410.7 million) since the fund launched.
The Clalit-Schneider model differs from traditional charity by combining immediate tax benefits with investment upside. The structure grew out of a funding gap that charitable donations alone cannot close. Donors who use a DAF to fund the pediatric venture can claim an immediate charitable deduction while potentially benefiting from fund returns—a dual-benefit structure that traditional grant-making cannot replicate.
Who Should Consider This Vehicle vs. Alternatives
This approach works best for: Tech founders and high-earner professionals with appreciated assets (stock, bonds, real estate gains). Over 50% of DAF holders in Israel come from the tech world, where stock-based giving has become sophisticated. If you have concentrated positions or significant capital gains, a DAF lets you donate appreciated assets without triggering capital gains tax, while still investing for growth.
Families with long-term giving horizons also benefit. The permanence of a DAF—funds can remain invested for decades—matches well with pediatric research, where breakthrough adoption takes years. Unlike one-time grants, a DAF compounds over time.
This approach is less suitable for: Donors seeking immediate, hands-on involvement in project selection. With a venture fund, investment decisions are made by professional managers (in this case, Ronen Gadot's team). You recommend—you do not control. Donors preferring direct say over fund allocation should consider traditional nonprofit grants or direct giving programs.
Also consider: If your priority is US tax efficiency, domestic DAFs remain superior. The Clalit-Schneider model is optimized for Israel-based or diaspora donors with Israel-focused giving intentions and access to Israeli securities.
| Feature | Clalit Pediatric VC (DAF Route) | Traditional Hospital Donation | Direct Tech Angel Investing |
|---|---|---|---|
| Tax benefit timing | Immediate (on DAF deposit) | Immediate (on donation) | None (capital gains if appreciated) |
| Investment upside | Yes (fund returns, tax-free) | No | Yes (company equity) |
| Control over allocation | Advisory (recommend grants) | Very low | Full (you choose companies) |
| Minimum entry | Varies by DAF sponsor | $1,000–$50,000 | $25,000–$500,000+ |
| Time to impact | Months to years | Immediate | 3–7 years (exit-dependent) |
| Complexity | Medium (professional managers) | Low | High (due diligence required) |
| Best for | Israel-focused philanthropists with tech wealth | One-time, direct hospital support | Hands-on investors with sector expertise |
The Post-October 7 Context
The for-profit initiative is the latest effort to use private investments, including from donor-advised funds, to stimulate innovation in the country's medical field post-Oct. This timing is significant. After October 7, 2023, Israeli healthcare systems faced both surge demand and funding pressure. Innovation funding via venture capital, rather than solely government grants, represents a strategic diversification.
For olim and diaspora donors, this signals a shift in how Israeli institutions are funding critical gaps. Rather than waiting for government or international aid, Clalit and Schneider are architecting a self-sustaining model: profits reinvest in research, and donor-advised vehicles allow international givers to participate without complexity.
What Happens to Your Money: The Data Advantage
It is built on the unique advantages of Schneider and Clalit Health Services: a combination of leading clinical expertise, extensive medical databases, an exceptional longitudinal record of patient care, and advanced artificial intelligence capabilities. This is the fund's actual moat. Unlike most venture funds, SCVC has access to one of the world's largest healthcare datasets and 30+ years of pediatric clinical data.
This reduces risk for the portfolio companies and increases their probability of regulatory approval and market fit. The fund operates as a separate entity but draws on the hospital's clinical settings and Clalit's data.
Frequently Asked Questions
Can I donate through a DAF directly to SCVC? Yes, but not all DAF sponsors support venture fund investments. Keshet and IsraelGives explicitly allow investment in Israeli funds and startups. Ask your DAF administrator. You will receive an immediate tax deduction for the DAF deposit, not the venture investment itself.
What if SCVC invests in a company that fails? Venture losses are absorbed by the fund. Your tax deduction (on the DAF deposit) stands. You do not have personal liability. This is a key difference from direct angel investing, where your loss mirrors your investment.
How do I recommend a grant from my DAF to Clalit-Schneider research? After deposits into a DAF, you recommend grants online or through your account manager. The DAF sponsor may conduct due diligence, but absent conflicts, your recommendation is typically honored within weeks. You can recommend grants quarterly or annually.
Is there a minimum to start? A Donor Advised Fund can be established with a minimum contribution of $10,000. Individual minimum investments in the venture fund itself may be higher—confirm with the fund sponsor. DAFs lower the barrier for diversified giving.
Bottom Line: Is This Right for You?
Clalit and Schneider have created a novel structure that solves a real problem: pediatric healthcare innovation is underfunded relative to its public health impact, yet traditional philanthropy alone cannot close the gap. By marrying venture capital returns with donor-advised fund tax efficiency, the model expands access to both.
For diaspora donors, tech wealth holders, and families with long-term Israel commitments, this vehicle is worth exploring—especially if you have appreciated assets and seek tax-efficient ways to fund innovation. For donors who prefer immediate, tangible project impact or hands-on involvement, traditional grants remain clearer.
In 2026, as Israeli healthcare systems navigate post-war recovery and innovation pressure, models like SCVC represent a maturing private-sector response. As we covered in our analysis of Israel's Healthcare System 2026 changes for new olim, institutional adaptation is accelerating across medical and insurance sectors.
The real differentiator for SCVC is not the venture structure itself—it is the data and clinical access. Few funds globally can claim partnership with a 30-year pediatric research institution and a HMO serving 4.5 million patients. That edge, combined with donor-advised fund flexibility, explains the fund's rapid first close. If pediatric health innovation aligns with your giving priorities, this is a legitimate place to direct philanthropic capital.
Further reading: Making Aliyah 2026: Process, Costs, Sal Klita, Documents — AliyaToday.
Further reading: Eilat Real Estate Investment 2026: Red Sea Resort Market Reality — Jewish Property Report.
Related Articles
Join Jewish News Now for weekly practical guides on benefits, housing, documents, and life in Israel.
Solly Marks is a Jewish news publisher covering Israel and the global Jewish community. JewishNewsNow delivers factual, pro-Israel journalism — breaking news, community updates, and analysis for the worldwide Jewish diaspora.